Clinical trials: Immunotherapy
Malignant Pleural Mesothelioma
Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma
This clinical trial will evaluate the safety and immune response of the sequential administration cancer vaccine CRS-207 (with or without cyclophosphamide) followed by standard of care chemotherapy (pemetrexed and cisplatin).
- Trial name
- NCT01675765
- Testing
- Immunotherapy plus chemotherapy, Immunotherapy with cyclophosphamide plus chemotherapy
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- Aduro Biotech, Inc.
Gastrointestinal Cancer, Immunotherapy
An Exploratory Trail of Camrelizumab Plus Apatinib Mesylate for Advanced Gastrointestinal
At present, surgery, radiotherapy and chemotherapy are the main treatment methods for patients with advanced gastrointestinal cancer.
- Conditions
- Gastrointestinal Cancer, Immunotherapy, Targeted Therapy
- Trial name
- NCT05225844
- Testing
- Camrelizumab, Apatinib Mesylate
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Harbin Medical University
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Patient Experiences of Multiple Sclerosis (PExMS)
Besides coping with the diagnosis, people with multiple sclerosis have to make complex decisions such as deciding about immunotherapies.
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Patient Engagement, Self Efficacy
- Trial name
- PExMS (NCT04236544)
- Testing
- PExMS and DECIMS-Wiki, DECIMS-Wiki
- Volunteers
- 55 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Non-Hodgkin Lymphoma
Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma
This is a randomized, open label, multicenter phase III trial comparing the efficacy, safety, and tolerability of tisagenlecleucel to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of…
- Trial name
- BELINDA (NCT03570892)
- Testing
- Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy, Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
- Where
- 67 sites in United States, Australia and 16 more
- Volunteers
- 330 people
- Sponsor
- Novartis Pharmaceuticals
Upper Tract Urothelial Carcinoma
NECTAR Study: Neoadjuvant Toripalimab + 9MW2821 for Local UTUC
The NECTAR study is a multicenter, open-label, randomized phase II clinical trial designed to evaluate a neoadjuvant treatment strategy in patients with localized upper tract urothelial carcinoma (UTUC).
- Trial name
- NECTAR (NCT07412171)
- Testing
- Toripalimab, 9MW2821, Radical Nephroureterectomy with or without Lymph Node Dissection
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University Third Hospital
Endocrine/Neuroendocrine, Non-Small Cell Lung Cancer
Non-Viral TCR Gene Therapy
Background: A person s white blood cells can be modified in a lab to recognize certain changes in their tumor. Many of these cells are collected from the person, modified, then given back to the person.
- Conditions
- Endocrine/Neuroendocrine, Non-Small Cell Lung Cancer, Breast Cancer, Gastrointestinal/Genitourinary Cancers
- Trial name
- NCT04102436
- Testing
- Fludarabine, Cyclophosphamide, Aldesleukin
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Gastric Cancer
Efficacy and Safety of Tirelizumab Plus Chemotherapy Versus Chemotherapy Alone in Patients With Lymph Node Positive Gastric Cancer After Surgery
Lymph node positive patients after D2 radical surgery for gastric cancer, who started to be treated at Yixing people's Hospital in April 2021, were selected and enrolled into the study group according to the patients' wishes…
- Trial name
- NCT05844371
- Testing
- tirelizumab, chemotherapy with oxaliplatin + heroda
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Yixing People's Hospital
Microsatellite Stable (MSS) Colorectal Adenocarcinomas, Colorectal Adenocarcinoma
Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer
The purpose of this study is to evaluate the safety and clinical activity of nivolumab and relatlimab in patients with metastatic or locally advanced microsatellite stable (MSS) colorectal cancer.
- Trial name
- NCT03642067
- Testing
- Nivolumab, Relatlimab
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
HLRCC, Sporadic Papillary Renal Cell Cancer
A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
Background: At the present time, there are no drugs that have been proven to work in patients with papillary kidney cancer that has spread (metastasized) beyond the kidneys.
- Trial name
- NCT01130519
- Testing
- Bevacizumab, Erlotinib
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- National Cancer Institute (NCI)
NSCLC (Non-small Cell Lung Cancer), Neoadjuvant Immunotherapy
A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLC
The goal of this clinical trial is to learn if tislelizumab in combination with anlotinib and platinum-based doublet chemotherapy works to treat for resectable stage II-IIIB driver gene-negative NSCLC.
- Conditions
- NSCLC (Non-small Cell Lung Cancer), Neoadjuvant Immunotherapy, Adjuvant Immunotherapy
- Trial name
- NCT06977828
- Testing
- tislelizumab in combination with anlotinib and platinum-based doublet chemotherapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Endometrial Cancer
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
The purpose of this study is to investigate the efficacy and safety of the lifileucel regimen in participants with previously treated endometrial cancer.
- Trial name
- NCT06481592
- Testing
- Lifileucel
- Where
- 12 sites in United States
- Volunteers
- 60 people
- Sponsor
- Iovance Biotherapeutics, Inc.
Stomach Neoplasms, Gastric Cancer
Neoadjuvant Immunotherapy Plus Chemotherapy in Borrmann Type 4 and Large Type 3 Gastric Cancer
The aim of this study is to test the efficacy and safety of immunotherapy plus chemotherapy on people with a relatively rare type of gastric cancer.
- Conditions
- Stomach Neoplasms, Gastric Cancer, Linitis Plastica of Stomach
- Trial name
- Neo-ICEBOAT (NCT06451211)
- Testing
- Tislelizumab, Oxaliplatin, S-1
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Sun Yat-sen University
Squamous Cell Carcinoma, Adenocarcinoma
Identification of Key Blood Molecular Markers for Immunotherapy
To identify unique blood markers in cancer patients so that we can identify patients with evidence of pre-existing immunity who may be a responder to immunotherapy.
- Conditions
- Squamous Cell Carcinoma, Adenocarcinoma, Neoplasms
- Trial name
- NCT00507702
- Testing
- phlebotomy
- Where
- United States
- Volunteers
- 191 people
- Sponsor
- Stanford University
Solid Tumors, Adult
A Clinical Study on the Efficacy and Mechanism of Tumor Treatment Vaccine (TTV) for Recurrent and Refractory Advanced Solid Tumors
This is a study of the clinical efficacy and mechanism study of tumor treatment vaccine (TTV, also known as Neo-BCV) in patients with recurrent and refractory advanced solid tumors.
- Trial name
- NCT05747339
- Testing
- tumor treatment vaccine injection
- Volunteers
- 50 people
- Sponsor
- Wuxi People's Hospital
Melanoma
Post-ATU Study of Nivolumab
Nivolumab obtained European Marketing authorization in June 2015. Before this date, a Temporary Authorization for Use (ATU) Program in France for nivolumab was set up between September 2014 and August 2015.
- Trial name
- Post-ATU (NCT03325257)
- Testing
- Routine care
- Where
- 17 sites in France
- Volunteers
- 350 people
- Sponsor
- Nantes University Hospital
Small Cell Lung Cancer Extensive Stage, Resistance to Immunotherapy
Sintilimab Plus Anlotinib as Second or Further-line Therapy for ES-SCLC Who Have Progressed After Anti-PD-1/L1 Therapy
The phase II study enrolled ES-SCLC patients who had disease progression after anti-PD-1/L1 therapy. Participants received intravenous sintilimab 200 mg on day one and oral daily anlotinib 8-12 mg on days 1-14 once every three…
- Trial name
- NCT07022301
- Testing
- sintilimab combined with anlotinib
- Volunteers
- 25 people
- Sponsor
- First Affiliated Hospital of Wannan Medical College
Pancreatic Cancer
Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer
The purpose of this study is to study the safety and clinical activity of nivolumab and ipilimumab in combination with either sequential administration of CY/GVAX pancreas vaccine followed by CRS-207 (Arm A) or with…
- Trial name
- NCT03190265
- Testing
- Cyclophosphamide, Nivolumab, Ipilimumab
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Non-Small Cell Lung Cancer, Small Cell Lung Cancer
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
QUILT-3.055 is a Phase 2b, open-label, multicohort study investigating combination immunotherapies in patients with advanced solid tumors who have previously been treated with PD-1/PD-L1 checkpoint inhibitors.
- Conditions
- Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT03228667
- Testing
- N-803 + Pembrolizumab, N-803 + Nivolumab, N-803 + Atezolizumab
- Where
- 35 sites in United States
- Volunteers
- 40 people
- Sponsor
- ImmunityBio, Inc.
Unresectable Gastric Cancer
A Retrospective Study of Immunotherapy in Conversion Therapy of Unresectable Gastric Cancer
This study was an observational, non-interventional, multicenter retrospective study to evaluate the feasibility and safety of sintilimab combined with chemotherapy (SOX or PS) in the clinical practice of unresectable locally…
- Trial name
- NCT05385809
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Zhejiang Cancer Hospital
Hepatocellular Carcinoma
Comparing the Combination of Trastuzumab and Regorafenib With Regorafenib Monotherapy for Advanced Hepatocellular Carcinoma After First-line Treatment
At present, there is no standard treatment plan for hepatocellular carcinoma after the progress of first-line target immunotherapy.
- Trial name
- NCT07078305
- Testing
- Regorafenib and tislelizumab, Regorafenib
- Volunteers
- 134 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.